Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176

Cancers (Basel). 2021 Jul 20;13(14):3624. doi: 10.3390/cancers13143624.

Edouard Auclin^{1

2}, Laura Mezquita^{3

4}, Benjamin Besse⁵

¹ Department of Medical and Thoracic Oncology, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Université de Paris, 75015 Paris, France.
² Centre d'Investifation Clinique (Epidémiologie Clinique) INSERM 1418, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, 75015 Paris, France.
³ Medical Oncology Department, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
⁴ Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, The August Pi i Sunyer Biomedical Research Institute IDIBAPS, 08036 Barcelona, Spain.
⁵ Department of Oncology, Institut Gustave Roussy, 94805 Villejuif, France.

Abstract

We read, with great interest, the recently published article by Hopkins et al. [...].